Article

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

2022-11-15

Abstract excerpt

Introduction: The interaction of menin with the epigenetic regulator KMT2A in acute leukemia with KMT2A rearrangement (KMT2Ar) or mutant NPM1 (mNPM1, NPM1c) leads to upregulation of leukemogenic genetic programs. Targeting the KMT2A-menin interaction downregulates aberrant expression of HOXA9 and MEIS1 and reverses leukemogenesis. KMT2Ar leukemia affects infants, children and adults and is associated with high rat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d3e39379-5d1a-5d22-9a2b-8e3a62db35a3
DOI: 10.1182/blood-2022-164849

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudyDOI 10.1182/blood-2022-164849Read

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasSemantic proximity Read

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity Read

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapiesSemantic proximity Read